KR20140019685A - Healthy and functional food for the improvement of blood flow - Google Patents
Healthy and functional food for the improvement of blood flow Download PDFInfo
- Publication number
- KR20140019685A KR20140019685A KR1020120086276A KR20120086276A KR20140019685A KR 20140019685 A KR20140019685 A KR 20140019685A KR 1020120086276 A KR1020120086276 A KR 1020120086276A KR 20120086276 A KR20120086276 A KR 20120086276A KR 20140019685 A KR20140019685 A KR 20140019685A
- Authority
- KR
- South Korea
- Prior art keywords
- vitamin
- extract powder
- blood flow
- blood
- lactose
- Prior art date
Links
- 230000017531 blood circulation Effects 0.000 title claims abstract description 43
- 235000013376 functional food Nutrition 0.000 title claims description 6
- 230000006872 improvement Effects 0.000 title abstract description 5
- 235000001497 healthy food Nutrition 0.000 title 1
- 230000036541 health Effects 0.000 claims abstract description 13
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 12
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 12
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims abstract description 12
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000000203 mixture Substances 0.000 claims abstract description 7
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims abstract description 6
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 6
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims abstract description 6
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims abstract description 6
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims abstract description 6
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims abstract description 6
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims abstract description 6
- 229930003779 Vitamin B12 Natural products 0.000 claims abstract description 6
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 6
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 6
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims abstract description 6
- 229910000365 copper sulfate Inorganic materials 0.000 claims abstract description 6
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 claims abstract description 6
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229960000367 inositol Drugs 0.000 claims abstract description 6
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims abstract description 6
- 239000000395 magnesium oxide Substances 0.000 claims abstract description 6
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims abstract description 6
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229950006780 n-acetylglucosamine Drugs 0.000 claims abstract description 6
- 235000005152 nicotinamide Nutrition 0.000 claims abstract description 6
- 239000011570 nicotinamide Substances 0.000 claims abstract description 6
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229960003080 taurine Drugs 0.000 claims abstract description 6
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims abstract description 6
- 235000019155 vitamin A Nutrition 0.000 claims abstract description 6
- 239000011719 vitamin A Substances 0.000 claims abstract description 6
- 235000019163 vitamin B12 Nutrition 0.000 claims abstract description 6
- 239000011715 vitamin B12 Substances 0.000 claims abstract description 6
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 6
- 239000011718 vitamin C Substances 0.000 claims abstract description 6
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 6
- 239000011709 vitamin E Substances 0.000 claims abstract description 6
- 229940046009 vitamin E Drugs 0.000 claims abstract description 6
- 229940045997 vitamin a Drugs 0.000 claims abstract description 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims abstract description 3
- 229930182816 L-glutamine Natural products 0.000 claims abstract description 3
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 claims abstract description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229960003512 nicotinic acid Drugs 0.000 claims abstract description 3
- 235000001968 nicotinic acid Nutrition 0.000 claims abstract description 3
- 239000011664 nicotinic acid Substances 0.000 claims abstract description 3
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims abstract 2
- 239000000843 powder Substances 0.000 claims description 43
- 239000000284 extract Substances 0.000 claims description 15
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 12
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 11
- 239000008101 lactose Substances 0.000 claims description 11
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 10
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 10
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 10
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 10
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 10
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 10
- CNNRPFQICPFDPO-UHFFFAOYSA-N octacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCO CNNRPFQICPFDPO-UHFFFAOYSA-N 0.000 claims description 10
- -1 textrin) 13% Substances 0.000 claims description 9
- 239000004365 Protease Substances 0.000 claims description 8
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 7
- 239000004310 lactic acid Substances 0.000 claims description 6
- 235000014655 lactic acid Nutrition 0.000 claims description 6
- 229960002666 1-octacosanol Drugs 0.000 claims description 5
- 241000383638 Allium nigrum Species 0.000 claims description 5
- 108010004032 Bromelains Proteins 0.000 claims description 5
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 5
- SEBIKDIMAPSUBY-ARYZWOCPSA-N Crocin Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)C(C)=CC=CC(C)=C\C=C\C=C(/C)\C=C\C=C(C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1)O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SEBIKDIMAPSUBY-ARYZWOCPSA-N 0.000 claims description 5
- 239000006000 Garlic extract Substances 0.000 claims description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 5
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 5
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims description 5
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims description 5
- 235000021355 Stearic acid Nutrition 0.000 claims description 5
- 235000019835 bromelain Nutrition 0.000 claims description 5
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 claims description 5
- 229920002678 cellulose Polymers 0.000 claims description 5
- 239000001913 cellulose Substances 0.000 claims description 5
- 235000017471 coenzyme Q10 Nutrition 0.000 claims description 5
- 229940110767 coenzyme Q10 Drugs 0.000 claims description 5
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 5
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 5
- 239000000194 fatty acid Substances 0.000 claims description 5
- 229930195729 fatty acid Natural products 0.000 claims description 5
- 229960000304 folic acid Drugs 0.000 claims description 5
- 235000019152 folic acid Nutrition 0.000 claims description 5
- 239000011724 folic acid Substances 0.000 claims description 5
- 239000009627 gardenia yellow Substances 0.000 claims description 5
- 235000020706 garlic extract Nutrition 0.000 claims description 5
- 235000011187 glycerol Nutrition 0.000 claims description 5
- 229940087603 grape seed extract Drugs 0.000 claims description 5
- 235000002532 grape seed extract Nutrition 0.000 claims description 5
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 5
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 5
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 5
- 229940013712 pineapple extract Drugs 0.000 claims description 5
- 235000005875 quercetin Nutrition 0.000 claims description 5
- 229960001285 quercetin Drugs 0.000 claims description 5
- 239000011669 selenium Substances 0.000 claims description 5
- 239000000377 silicon dioxide Substances 0.000 claims description 5
- 235000012239 silicon dioxide Nutrition 0.000 claims description 5
- 235000003687 soy isoflavones Nutrition 0.000 claims description 5
- 239000008117 stearic acid Substances 0.000 claims description 5
- 239000001717 vitis vinifera seed extract Substances 0.000 claims description 5
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 4
- 229930064664 L-arginine Natural products 0.000 claims description 4
- 235000014852 L-arginine Nutrition 0.000 claims description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 3
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 claims description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 2
- 235000015872 dietary supplement Nutrition 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 229940002508 ginger extract Drugs 0.000 claims description 2
- 235000020708 ginger extract Nutrition 0.000 claims description 2
- 239000008267 milk Substances 0.000 claims description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 2
- 229910052711 selenium Inorganic materials 0.000 claims description 2
- 239000004408 titanium dioxide Substances 0.000 claims description 2
- 235000019158 vitamin B6 Nutrition 0.000 claims description 2
- 239000011726 vitamin B6 Substances 0.000 claims description 2
- 229940011671 vitamin b6 Drugs 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims 1
- 241000282374 Puma concolor Species 0.000 claims 1
- 235000013402 health food Nutrition 0.000 abstract description 3
- 238000009835 boiling Methods 0.000 abstract 1
- 238000001816 cooling Methods 0.000 abstract 1
- 210000004204 blood vessel Anatomy 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 235000013305 food Nutrition 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 201000010099 disease Diseases 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 6
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 6
- 208000007536 Thrombosis Diseases 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 229960002477 riboflavin Drugs 0.000 description 6
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 206010003210 Arteriosclerosis Diseases 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 235000020717 hawthorn extract Nutrition 0.000 description 4
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 235000002789 Panax ginseng Nutrition 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
- FCASKLHVRFDIJB-UHFFFAOYSA-N Riboflavine Natural products Cc1cc2N=C3C(NC(=O)NC3=O)N(CC(O)C(O)C(O)CO)c2cc1C FCASKLHVRFDIJB-UHFFFAOYSA-N 0.000 description 3
- 229930003471 Vitamin B2 Natural products 0.000 description 3
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 235000013734 beta-carotene Nutrition 0.000 description 3
- 239000011648 beta-carotene Substances 0.000 description 3
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 3
- 229960002747 betacarotene Drugs 0.000 description 3
- 210000001772 blood platelet Anatomy 0.000 description 3
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 3
- 229960002079 calcium pantothenate Drugs 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000001103 potassium chloride Substances 0.000 description 3
- 235000011164 potassium chloride Nutrition 0.000 description 3
- 235000019419 proteases Nutrition 0.000 description 3
- 235000019192 riboflavin Nutrition 0.000 description 3
- 239000002151 riboflavin Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 235000020712 soy bean extract Nutrition 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 235000019164 vitamin B2 Nutrition 0.000 description 3
- 239000011716 vitamin B2 Substances 0.000 description 3
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 150000002301 glucosamine derivatives Chemical class 0.000 description 2
- KIAUZNJUKYZETG-UHFFFAOYSA-N iron phosphoric acid Chemical compound [Fe].P(O)(O)(O)=O.[Fe] KIAUZNJUKYZETG-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- OPPDZGGNDGEPAW-RVZXSAGBSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2,5-diamino-5-oxopentanoic acid Chemical compound NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(N)=O OPPDZGGNDGEPAW-RVZXSAGBSA-N 0.000 description 1
- UUGUGLBRYMQUHN-UHFFFAOYSA-N 2-hydroxypropanoic acid;iron Chemical compound [Fe].CC(O)C(O)=O UUGUGLBRYMQUHN-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- KWTQSFXGGICVPE-WCCKRBBISA-N Arginine hydrochloride Chemical compound Cl.OC(=O)[C@@H](N)CCCN=C(N)N KWTQSFXGGICVPE-WCCKRBBISA-N 0.000 description 1
- 240000001548 Camellia japonica Species 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 240000001890 Ribes hudsonianum Species 0.000 description 1
- 235000016954 Ribes hudsonianum Nutrition 0.000 description 1
- 235000001466 Ribes nigrum Nutrition 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 102000019997 adhesion receptor Human genes 0.000 description 1
- 108010013985 adhesion receptor Proteins 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 235000018597 common camellia Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 210000000497 foam cell Anatomy 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- RFGNMWINQUUNKG-UHFFFAOYSA-N iron phosphoric acid Chemical compound [Fe].OP(O)(O)=O RFGNMWINQUUNKG-UHFFFAOYSA-N 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 208000023516 stroke disease Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000021076 total caloric intake Nutrition 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000009441 vascular protection Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/326—Foods, ingredients or supplements having a functional effect on health having effect on cardiovascular health
Abstract
Description
본 발명은 사람들이 복용함으로써 혈류량을 개선함으로써 건강유지에 도움을 줄 수 있는 혈류량 개선을 위한 건강기능식품에 관한 것이다.BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a health functional food for improving blood flow which can help maintain health by improving blood flow by taking by people.
최근, 식생활의 서구화, 운동 부족, 과도한 스트레스 등의 생활 환경의 변화에 따라 동맥경화증, 뇌경색 등의 혈액이나 순환기계에 관련한 질환 및 고지혈증, 당뇨병 등의 혈액 순환에 악영향을 미치는 질환이 증가되고 있다. 이들 질환은 미소 혈관이나 모세혈관의 혈류의 저하를 일으키므로 생체에 다양한 악영향을 줄 위험성이 지적되고 있다. 또한, 혈류가 피부의 가려움, 피로, 고혈압 등과도 관계가 있는 것도 보고되고 있다.Recently, diseases affecting blood circulation such as atherosclerosis, cerebral infarction and the like, and blood circulation such as hyperlipemia and diabetes are increasing due to changes in the living environment such as westernization of diet, lack of exercise, and excessive stress. These diseases cause a decrease in blood flow of microvasculature and capillary blood vessels, and thus, there is a danger that various diseases may be adversely affected. It has also been reported that blood flow is also associated with itching, fatigue, hypertension, and the like of the skin.
일반적으로 혈액순환(the circulation of blood)즉, 혈류는 혈액이 심장을 중심으로 혈관을 따라 우리의 신체를 순환하는 것으로 산소를 신체 각 조직에 공급하고 탄산가스를 방출하고, 영양소를 보급하고 대사산물을 방출하며, 여러 내분비선에서 호르몬을 운반하여 특정기관의 기능을 조절하며 그밖에 병원균 조절작용과 체온조절, 삼투압조절, 수분조절 등의 기능을 수행하는 과정이다. 혈관은 동백, 모세혈관, 정맥으로 구성되어 있다. 동맥은 외탄력선판과 결합조직으로 되어 있는 외막, 평활근이 많고 그 안에 다수의 탄력섬유를 함유하고 있는 중막, 제일 안쪽의 내피세포와 그것을 둘러싸고 있는 결합조직과 탄력섬유가 모여서 내강성판으로 되어 있는 내막으로 이루어져 있다. 모세혈관은 소동맥과 소정맥이 연결된 것으로 그물모양으로 가늘게 가지가 나 있으며 직경 0.008~0.02mm의 가는관으로서 적혈구가 통과될 정도이고 육안으로는 보이지 않으며, 이 모세혈관을 통해서 혈액 중의 산소와 영양분은 조직내로 보내지고 조직에서 만들어진 이산화탄소(CO2)나 노폐물은 혈관으로 들어온다. 정맥의 외막은 비교적 두껍고 내막과 중막은 얇으며 압력이 없고 다른 혈관에 비해 혈류가 약하여 심장보다 낮은 부분의 정맥에서 역류할 위험성이 있기 때문에 역류 방지용 판막(valve)이 붙어 있다.The circulation of blood, that is, the blood circulation around the heart around the blood circulation of our body by supplying oxygen to the body tissues, carbon dioxide emissions, nutrients, and metabolic products And hormone transport in various endocrine glands to regulate the function of specific organs, as well as pathogen control, body temperature control, osmotic pressure control, moisture control is a process to perform functions. The blood vessels consist of camellias, capillaries, and veins. The artery is composed of an outer membrane composed of an external elastic plate and connective tissue, a middle membrane containing many smooth muscles and a large number of elastic fibers therein, an inner membrane of the innermost endothelial cells, a connective tissue surrounding the inner membrane, Lt; / RTI > The capillary blood vessels are connected with the small arteries and the parietal arteries. They have a narrow net shape and are thin tubes with a diameter of 0.008-0.02mm. They pass through red blood cells and are not visible to the naked eye. Through this capillaries, oxygen and nutrients in blood And the carbon dioxide (CO2) and wastes produced by the tissue enter the blood vessel. The outer membrane of the vein is relatively thick, the inner membrane and the middle membrane are thin, and there is a valve to prevent backflow because there is no pressure and there is a risk of backflow in the vein lower than the heart due to weaker blood flow than other blood vessels.
또한, 혈액순환 장애란 우리 온몸의 구석구석에 뻗어 있는 혈관이 탄력을 잃고 내벽에 콜레스테롤 등이 침착되어 혈관 내강이 좁아져 혈액 순환이 원활이 이루어지지 못하는 것을 말한다. 혈액순환 장애는 손발 차고 저림, 뒷목 당김, 어깨 결림, 기억력 감퇴, 무기력, 집중력 약화, 현기증 및 만성 피로 증상을 유발하여 정상적인 생활을 영위하는데 어려움이 많게 된다.In addition, blood circulation disorder means that the blood vessels extending to all corners of our body lose their elasticity and cholesterol is deposited on the inner wall, and the blood circulation is not smooth due to narrowing of the lumen. Blood circulation disorder causes difficulty in maintaining normal life by causing limbs, limbs, stiff shoulders, memory loss, weakness, weakness of concentration, dizziness and chronic fatigue symptoms.
혈액순환에 장애가 생겨 발생하는 심혈관계 질환으로 고혈압, 동맥경화증, 심장병, 뇌졸중 등은 오늘날 성인병의 주종을 이루고 있으며 사망률이 높은 질병으로 70세까지는 암에 의한 사망률이 가장 높으나 70세 이후에는 심혈관계 질환이 제 1의 사망원인이다. 이러한 심혈관계 질환은 서로 밀접한 관련이 있는데, 이미 상술한 바와 같이 급속한 경제의 발전, 식생활의 발전, 사회 환경의 변화와 서구화로 질병양상이 서구화되어 가면서 증가하고 있으며, 총 칼로리 섭취 증가와 지방섭취 증가로 콜레스테롤을 비롯하여 혈중 지질치의 현저한 상승을 초래하여 관상동맥질환, 뇌졸중, 말초혈관질환과 같은 동맥경화성 심혈관 질환 발생도 현저히 증가하고 있다. 고지혈증, 동맥경화증, 심근 경색증 및 뇌혈전증 등 심혈관계 질환의 발생원인은 높은 지방함량과 식이섬유 함량이 적은 가공식품의 섭취, 유전적인 요인, 흡연, 음주, 고혈압, 당뇨, 비만, 운동부족, 과도한 스트레스 등이 관여한다고 널리 알려져 있으며, 이러한 심혈관계 질환을 일으키는 기본적인 병변은 동맥경화증으로 그 원인에 대한 역학적 및 실험적 연구로 다양한 위험인자를 밝혀내고 있다. 이러한 병변의 발생과정을 살펴보면, 물리적 또는 화학적인 상처는 혈관의 단층세포표면에 손상을 야기하고, 혈관벽에 혈전 생성을 유도할 수 있는 혈전 부착 수용체가 발현되고, 여기에 단구(monocyte), T-임파구(T-lympocyte) 및 혈소판 등이 부착하여, 혈관 내막세포 사이를 통하여 혈관벽 속으로 침윤하게 되는데, 이때, 혈액 속의 지질단백질도 함께 유입된다. 혈관벽 내부로 유입된 단구들은 지질단백질을 탐식하여 대식세포(macrophage)로 변형되고, 대식세포들은 콜레스테롤을 축적하여 포말세포(form cells)를 형성한다. 포말세포들은 염증반응과 세포성장을 반복하면서 혈관벽을 파괴하거나 비후하여, 혈액중의 혈소판이 점착됨으로 혈전을 형성하게 한다. 이러한 진행과정은 결국, 동맥경화에 의한 혈관의 협착과 혈전에 의한 혈관의 완전 폐쇠로 심장으로의 혈액공급이 순간적으로 차단되어, 심근경색에 의한 사망을 유도한다.It is a major cardiovascular disease caused by obstruction of blood circulation. Hypertension, arteriosclerosis, heart disease, stroke are the major diseases of today's adult diseases and mortality rate is the highest. Cancer death rate is the highest until 70 years old. This is the first cause of death. These cardiovascular diseases are closely related to each other. As already mentioned above, as the development of the economy, the development of the eating habits, the change of the social environment and westernization, the disease pattern is increasing as westernized, and the increase in total calorie intake and fat intake As a result, the incidence of atherosclerotic cardiovascular diseases such as coronary artery disease, stroke, and peripheral vascular disease is remarkably increased due to a significant increase in blood lipid levels including cholesterol. The causes of cardiovascular diseases such as hyperlipidemia, atherosclerosis, myocardial infarction and cerebral thrombosis are caused by intake of high fat content and processed foods with low dietary fiber content, genetic factors, smoking, drinking, hypertension, diabetes, obesity, lack of exercise, . These basic cardiovascular disease-causing lesions are arteriosclerosis, which is characterized by epidemiological and experimental studies on the etiology and causes of various risk factors. These lesions are characterized by physical or chemical scars that cause damage to the surface of the monolayer of blood vessels, and thrombus adhesion receptors capable of inducing thrombus formation in the blood vessel wall are expressed. Monocytes, T- T-lympocytes and platelets adhere to the blood vessels through the vascular endothelial cells. At this time, lipid proteins in the blood also enter the blood vessels. The monoliths that enter the blood vessel wall digest lipid proteins and transform them into macrophages, and macrophages accumulate cholesterol to form cells. Foam cells break inflammatory reaction and cell growth while destroying or enlarging the blood vessel wall, causing blood platelets to adhere to form blood clots. This progression eventually leads to myocardial infarction death by momentarily blocking blood supply to the heart due to stenosis of the blood vessel due to arteriosclerosis and complete closure of the blood vessel due to thrombus.
특히 혈류는 고혈당에 의해 혈액의 유동성, 적혈구나 백혈구의 유연성 또는 혈소판의 응집능력 등의 영향을 받게 된다. 특히, 적혈구 및 백혈구 등의 혈구는 혈액 체적의 약 40%를 차지한다고 하며, 미세한 혈관에서는 특히 혈액의 유동성에 영향을 준다. 이러한 혈류가 저하되는 상태가 오래 계속되면, 예를 들면, 혈관의 유연성이 상실되며 적혈구의 유연성이 나빠지는 미소 혈관에서 적혈구 또는 백혈구가 막히기 쉬워지는 혈전을 형성하기 쉬워지는 등의 현상을 야기하며, 순환기계 질환의 발병의 한가지 원인으로 된다. 중독인 경우에는 혈액의 흐름이 중지되며 이의 주변부에서 조직의 괴사가 일어난다. 그러므로, 「생체내의 혈액의 유동 용이성」은 건강을 유지하는 데에 중요시되게 되어 있다.Particularly, blood flow is influenced by blood flow, the flexibility of red blood cells, leukocytes, or the ability of platelets to aggregate due to hyperglycemia. In particular, blood cells such as red blood cells and leukocytes account for about 40% of the blood volume, and it affects the fluidity of blood particularly in fine blood vessels. Such a state in which the blood flow is lowered for a long time causes, for example, a phenomenon that the flexibility of the blood vessel is lost and the blood clot that makes the erythrocyte or leukocyte clogged easily in the micro blood vessel where the flexibility of the red blood cell is bad, It is one of the causes of circulatory disease. In the case of poisoning, blood flow stops and tissue necrosis occurs at the periphery of the blood. Therefore, " ease of flow of blood in the living body " is important for maintaining health.
따라서 혈류를 개선시킬 가능성이 있는 식품 및 식품 성분이 다수 개발 보고되어 있다. 예를 들면, 가까운 식품재로서는 흑식초, 매실 장아찌 등을 들 수 있다. 또한, 일본 공개특허공보 제(평)7-138168호에서는 어류 담즙의 극성 용매 추출물이 혈액의 유동성을 개선시키는 것이 보고되어 있다. 또한, 일본 공개특허공보 제2002-97143호에서는 글루코사민염 또는 글루코사민 유도체가 혈전 예방 또는 혈액의 유동성을 개선시키는 것이 보고되어 있다. 그러나, 혈류 개선은 주로 혈액의 유동성에 관한 작용에 기인한 것이 대부분이며, 혈류의 개선과 동시에 혈관의 강도나 탄력성의 개선, 즉 혈관 보호 효과를 갖는 성분을 배합한 식품 또는 의약 조성물은 제공되고 있지 않다. 한편, 일본 공개특허공보 제2000-135071호에는 혈관의 강화 작용에 관해서, 와인 착즙박 추출물이 폴리페놀 함유 추출물보다 우수한 효과를 갖는 것이 개시되어 있다. 그러나 혈액의 유동성에 관해서는 아무런 검토가 실시되고 있지 않다.Therefore, a number of food and food ingredients that have the potential to improve blood flow have been reported. For example, black foods such as blackcurrant, plum pickles and the like can be cited as the near food materials. In addition, in JP-A-7-138168, it has been reported that the polar solvent extract of fish bile improves the fluidity of blood. Also, in JP-A-2002-97143, glucosamine salts or glucosamine derivatives have been reported to prevent thrombosis or to improve the fluidity of blood. However, most of the improvement of the blood flow is mainly due to the action on the fluidity of the blood, and a food or medicinal composition containing the components having blood vessel protection effect, that is, improvement of blood flow and improvement of blood vessel strength or elasticity not. On the other hand, Japanese Patent Application Laid-Open No. 2000-135071 discloses that the wine-extract paste extract has an effect superior to that of the polyphenol-containing extract in terms of blood vessel strengthening action. However, there has been no study on the fluidity of blood.
따라서, 참된 의미에서 생체내에서의 혈류의 개선, 즉 혈액의 유동성을 개선시키며, 우수한 혈관 보호 효과를 갖는 혈액유동성 개선 조성물이 요망되고 있다.
Therefore, in a true sense, there is a demand for a composition for improving blood flow in vivo, that is, improving blood flowability and having an excellent vascular protection effect.
본 발명은 상기와 같은 점들은 감안하여 발명된 것으로서, 그 목적은 혈류량을 개선함으로써 인체의 건강유지에 도움을 줄 수 있는 혈류량 개선을 위한 건강기능식품을 제공함에 있다. The present invention has been made in view of the above problems, and an object thereof is to provide a health functional food for improving blood flow which can help maintain the health of a human body by improving blood flow.
본 발명의 목적은 건강보조식품을 제조함에 있어서, 비타민A 0.134%, 비타민B1 염산염 0.027%, 비타민C 15%, 비타민E 혼합제제 1.12%, 비타민B12 0.0008%, 니코틴산아미드(나이아신) 0.32%, 황산동 0.102%, 산화마그네슘 1.7%, L-글루타민 5.55%, L-라이신염산염 5.55%, N-아세틸글루코사민 1.4%, 이노시톨 2.45%, 타우린 6.95%, 파인애플추출물분말(브로멜라인) 6.95%, 코엔자임Q10 0.84%, 케르세틴 0.7%, 옥타코사놀 0.5%, 산사자추출분말 2.28%, 포도종자추출물분말 1.6700%, 유산균발효흑마늘추출물분말 0.83%, 혼합유당(또는 유당혼합-우유, 텍스트린) 13%, 스테아린산 1.2%, 이산화규소 1.2%, 유당가수분해물분말 6%, 대두이소플라본 0.5%, 결정셀룰로오스 17.1706%, 히드록시프로필메틸셀룰로오스(HPMC) 2.1%, 글리세린지방산에스테르(Almax-5000) 0.21%, 이산화티타늄 0.7%, 치자황색소 0.2%, 비타민B6 0.009%~0.04%, 엽산 0.001%~0.007%, 파라다이스넛추출물분말(셀렌) 0.005%~0.2%, 푸르마산제일철 0.005%~0.2%, L-아르기닌 0.5%~2%, 카르복시메틸셀룰로오스 칼슘 0.5%~2%, 뽕나무잎추출분말 또는 생강추출분말 1%~2%를 포함하는 것을 특징으로 하는 혈류량 개선을 위한 건강기능식품에 의해 달성될 수 있다.
An object of the present invention in the manufacture of dietary supplements, vitamin A 0.134%, vitamin B1 hydrochloride 0.027%,
이상에서 살펴본 바와 같이 본 발명에 따른 혈류량 개선을 위한 건강기능식품은 다양한 활성화 물질을 포함하고 있어 복용시 혈류량을 개선함으로써 인체 건강 유지에 도움을 줄 수 있는 효과를 갖는 것이다.
As described above, the health functional food for improving blood flow according to the present invention contains various activating substances and has an effect of helping to maintain human health by improving blood flow during taking.
도 1은 실시예 1에 따른 혈류량 변화를 나타내는 그래프
도 2는 실시예 2에 따른 혈류량 변화를 나타내는 그래프
도 3은 실시예 3에 따른 혈류량 변화를 나타내는 그래프1 is a graph showing changes in blood flow volume according to Example 1
2 is a graph showing changes in blood flow volume according to Example 2
Fig. 3 is a graph showing changes in blood flow volume according to the third embodiment
이하에서는 본 발명의 바람직한 실시예를 보다 구체적으로 살펴본다.Hereinafter, preferred embodiments of the present invention will be described in more detail.
이하의 실시예에서 나타나는 y 는 해당성분이 포함된 것을 의미하고, 공란은 포함하지 않고 있음을 의미한다. In the following examples, y means that the corresponding component is included, and does not include a blank.
도 1 내지 도 3에는 각각의 실시예에 따라 제조된 건강식품을 섭취한 후의 시간 흐름에 따른 혈류량 변화를 나타내고 있다.
1 to 3 show changes in blood flow over time after ingesting the health food prepared according to each embodiment.
실시예 1에는 아래의 표 1과 같은 성분으로 식품을 구성하였다. In Example 1, food was composed of the ingredients shown in Table 1 below.
도 1은 실시예 1에 따라 제조된 식품을 정제로 하여 1000mg 2알을 섭취한 경우의 1일 차 내지 4일 차의 혈류량 변화를 나타내고 있다. 그래프에 나타난 바와 같이 식품을 섭취하지 않은 경우 새벽 시간에 혈류량이 약 13000μ㎥/s 정도로 비교적 높게 유지하다가 아침시간이 되면서 급격하게 저하되고 있는 반면 실시예 1에 따른 식품을 섭취한 경우 1일 차에는 오후 7시경을 지나면서 혈류가 급격하게 상승하고 있고, 2일 차에는 오후 2시경으로 혈류상승 개시 시간이 당겨졌으며, 4일 차에는 오후 3시경에 상승하는 것은 물론 상승량도 25000μ㎥/s 로 매우 높게 나타나고 있다.
Fig. 1 shows changes in the blood flow of day 1 to
실시예 2는 아래의 표 2과 같은 성분으로 식품을 구성하였다. Example 2 constituted food with the ingredients shown in Table 2 below.
도 2에는 실시예 2에 따라 제조된 식품을 정제로 하여 650mg 2알을 섭취한 경우의 1일 차 내지 5일 차의 혈류량 변화를 나타내고 있다.FIG. 2 shows changes in the blood flow of day 1 to
그래프에 나타난 바와 같이 실시예 2에 따른 식품을 섭취한 경우 1일차에는 오후 2시경을 지나면서 혈류가 급격하게 상승하고 있고, 4일 차 및 5일 차에는 오전 11시경을 전후하여 혈류가 상승하여 약 18000~20000μ㎥/s 로 매우 높게 나타나고 있다.
As shown in the graph, when the food according to Example 2 was consumed, the blood flow rapidly increased after about 2:00 pm on the first day, and the blood flow increased around 11:00 am on the fourth and fifth day It is very high, about 18000 ~ 20000m3 / s.
실시예 3은 아래의 표 3과 같은 성분으로 식품을 구성하였다. Example 3 was composed of the ingredients shown in Table 3 below.
도 3에는 실시예 3에 따라 제조된 식품을 정제로하여 1000mg 2알을 섭취 한경우의 1일 차 및 2일 차의 혈류량 변화를 나타내고 있다.FIG. 3 shows changes in blood flow on day 1 and
그래프에 나타난 바와 같이 실시예 2에 따른 식품을 섭취한 경우 1일 차에는 오후 3시경을 지나면서 혈류가 상승하여 약 13000μ㎥/s를 유지하고 있으며, 2일 차에는 오후 5시경에 혈류가 약 20000μ㎥/s 까지 매우 높게 상승하는 것을 알 수 있다.As shown in the graph, when the food according to Example 2 was consumed, the blood flow increased to about 13000 mu m < 3 > / s after about 3 pm in the tea on day 1, It can be seen that it rises very high up to 20000 mu m < 3 > / s.
Claims (1)
In preparing health supplements, vitamin A 0.134%, vitamin B1 hydrochloride 0.027%, vitamin C 15%, vitamin E mixture formulation 1.12%, vitamin B12 0.0008%, nicotinic acid amide (niacin) 0.32%, copper sulfate 0.102%, magnesium oxide 1.7%, L-glutamine 5.55%, L-lysine hydrochloride 5.55%, N-acetylglucosamine 1.4%, inositol 2.45%, taurine 6.95%, pineapple extract powder (bromelain) 6.95%, coenzyme Q10 0.84%, quercetin 0.7% , Octacosanol 0.5%, mountain lion extract powder 2.28%, grape seed extract powder 1.6700%, lactic acid bacteria fermented black garlic extract powder 0.83%, mixed lactose (or lactose mixed-milk, textrin) 13%, stearic acid 1.2%, silicon dioxide 1.2%, Lactose hydrolyzate powder 6%, soy isoflavone 0.5%, crystalline cellulose 17.1706%, hydroxypropyl methyl cellulose (HPMC) 2.1%, glycerin fatty acid ester (Almax-5000) 0.21%, titanium dioxide 0.7%, gardenia yellow 0.2% , Vitamin B6 0.009% ~ 0.04%, Folic acid 0.001% ~ 0.007% , Paradise Nut Extract Powder (Selenium) 0.005% ~ 0.2%, Ferrous Fermatate 0.005% ~ 0.2%, L-Arginine 0.5% ~ 2%, Carboxymethyl Cellulose Calcium 0.5% ~ 2%, Mulberry Leaf Extract Powder or Ginger Extract Powder Health functional food for improving blood flow, comprising 1% to 2%
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120086276A KR101424335B1 (en) | 2012-08-07 | 2012-08-07 | Healthy and functional food for the improvement of blood flow |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120086276A KR101424335B1 (en) | 2012-08-07 | 2012-08-07 | Healthy and functional food for the improvement of blood flow |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20140019685A true KR20140019685A (en) | 2014-02-17 |
KR101424335B1 KR101424335B1 (en) | 2014-07-28 |
Family
ID=50267076
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020120086276A KR101424335B1 (en) | 2012-08-07 | 2012-08-07 | Healthy and functional food for the improvement of blood flow |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101424335B1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101469801B1 (en) * | 2014-05-09 | 2014-12-05 | 주식회사 웰솔루션 | Health functional food composition for facilitation of blood circulation or enhancement of capillary activity |
KR20160022172A (en) | 2014-08-19 | 2016-02-29 | 주식회사 엘지생활건강 | Composition for improving male health |
KR20170102932A (en) * | 2015-01-02 | 2017-09-12 | 멜라루카, 인크. | Composite supplement composition |
WO2020045717A1 (en) * | 2018-08-27 | 2020-03-05 | 스타링포스 주식회사 | Health functional food for ameliorating and preventing capillary hemorrhage |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102157662B1 (en) | 2018-10-26 | 2020-09-18 | 대전대학교 산학협력단 | Compositions comprising extract of Crataegi fructus and Lycopus lucidus for prevention or treatment of lipid-related cardiovascular diseases or obesity |
KR102310234B1 (en) | 2019-09-06 | 2021-10-08 | 경방신약(주) | Health functional food composition for improving blood circulation, and the method for preparing the same |
KR102310233B1 (en) | 2019-09-06 | 2021-10-08 | 경방신약(주) | Health functional food composition for improving blood circulation, and the method for preparing the same |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101205763B1 (en) * | 2005-06-23 | 2012-11-28 | 주식회사 엘지생활건강 | Cosmetic composition for improvement of blood flow |
KR101273304B1 (en) * | 2005-12-29 | 2013-06-11 | 주식회사 엘지생활건강 | Composition for improvement of blood flow or activation of cell growth |
-
2012
- 2012-08-07 KR KR1020120086276A patent/KR101424335B1/en active IP Right Review Request
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101469801B1 (en) * | 2014-05-09 | 2014-12-05 | 주식회사 웰솔루션 | Health functional food composition for facilitation of blood circulation or enhancement of capillary activity |
WO2015170881A1 (en) * | 2014-05-09 | 2015-11-12 | 주식회사 웰솔루션 | Blood circulation improving or capillary activity increasing health functional food composition |
KR20160022172A (en) | 2014-08-19 | 2016-02-29 | 주식회사 엘지생활건강 | Composition for improving male health |
KR20170102932A (en) * | 2015-01-02 | 2017-09-12 | 멜라루카, 인크. | Composite supplement composition |
WO2020045717A1 (en) * | 2018-08-27 | 2020-03-05 | 스타링포스 주식회사 | Health functional food for ameliorating and preventing capillary hemorrhage |
KR20200023938A (en) * | 2018-08-27 | 2020-03-06 | 스타링포스 주식회사 | Functional food for improving and preventing capillary hemorrhage |
Also Published As
Publication number | Publication date |
---|---|
KR101424335B1 (en) | 2014-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101424335B1 (en) | Healthy and functional food for the improvement of blood flow | |
CN101574140B (en) | Drink composition with human immunity strengthening and anti-fatigue functions | |
CN102292093B (en) | Composition from sphaeranthus indicus and garcinia mangostana for the control of metabolic syndrome | |
CN103211150B (en) | Polypeptide food containing active earthworm protein | |
US10149882B2 (en) | Weight management systems and related methods | |
CN104146259B (en) | A kind of health-care flour for diabetic and preparation method thereof | |
TWI721248B (en) | Anti-fatigue composition used for increasing endurance performance | |
CN101491334A (en) | Health food with immunity reinforcement function | |
CN105028868A (en) | Black garlic, black onion and black soybean peptide chewable tablet and preparation method thereof | |
CN104839680A (en) | Medical formula food for people with cardiovascular diseases | |
CN104839707A (en) | Yin deficiency physique non-total nutrient formula food | |
CN104855975A (en) | Non-total-nutrient formula food for sarcopenia syndrome | |
CN101108227A (en) | Konjak extractive powder capsule | |
CN104839698A (en) | Cardiovascular disease non-total nutrient formula food | |
CN104172168A (en) | Convenient food capable of alleviating atherosclerosis | |
Dange et al. | Effect of apple on fasting blood sugar and plasma lipids levels in type II diabetes | |
CN103384477B (en) | For having the composition of the functional food recovering blood constitute and function | |
CN104126791A (en) | Micro-ecological special dietary for atherosclerotic patients to eat | |
CN104855965A (en) | Non-full nutritional formula food for patients with atherosclerosis | |
CN101766306A (en) | Body-beautifying flammukinan health capsule | |
CN108094858A (en) | It is suitble to the nutritional staple food of patients with diabetes mellitus | |
CN104256266A (en) | Brain-tonifying and refreshing breakfast nutriment and preparation method thereof | |
KR100656241B1 (en) | The extract of Korean fermented soybean with inhibitory effect on hyperlipemia and platelet aggregation, and their composition | |
CN103845581A (en) | Natural green composition and application thereof to preventing and treating diabetes | |
CN103039614A (en) | Blueberry soymilk and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
N231 | Notification of change of applicant | ||
GRNT | Written decision to grant | ||
J204 | Invalidation trial for patent | ||
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2015100004128; TRIAL DECISION FOR INVALIDATION REQUESTED 20150803 Effective date: 20170317 |
|
FPAY | Annual fee payment |
Payment date: 20170612 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20180516 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20190515 Year of fee payment: 6 |